Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Ontology highlight
ABSTRACT: Mesothelin (MSLN) is a cell surface glycoprotein normally expressed only on serosal surfaces, and not found in the parenchyma of vital organs. Many solid tumors also express MSLN, including mesothelioma and pancreatic adenocarcinoma. Due to this favorable expression profile, MSLN represents a viable target for directed anti-neoplastic therapies, such as recombinant immunotoxins (iToxs). Pre-clinical testing of MSLN-targeted iTox's has yielded a strong body of evidence for activity against a number of solid tumors. This has led to multiple clinical trials, testing the safety and efficacy of the clinical leads SS1P and LMB-100. While promising clinical results have been observed, neutralizing anti-drug antibody (ADA) formation presents a major challenge to overcome in the therapeutic develop
SUBMITTER: Hagerty BL
PROVIDER: S-EPMC7408136 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA